Document:

exv4w8

POLYMEDIX, INC.

WARRANT TO PURCHASE COMMON STOCK

To Purchase [     ] Shares of Common Stock

Date of Issuance: _______, 2008

VOID
AFTER             , 2013

     THIS CERTIFIES THAT, for value received, [                    ], or permitted registered assigns (the
“Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from
PolyMedix, Inc., a Delaware corporation (the “Company”), up to [                    ] shares of the common
stock of the Company, par value $0.001 per share (the “Common Stock”). This warrant is one of a
series of warrants issued by the Company as of the date hereof (individually a “Warrant”,
collectively, “Company Warrants”) pursuant to that
certain Amended and Restated Co-Placement Agent Agreement among the
Company, Fordham Financial Management, Inc. and Carter Securities,
LLC , dated as of June ___, 2008.

     1. DEFINITIONS. As used herein, the following terms shall have the following respective meanings:

          (a) “Exercise Period” shall mean the period commencing with the date hereof and ending five
years from the effective date of the Company’s registration statement pursuant to which this
Warrant is issued, unless sooner terminated as provided below.

          (b) “Exercise Price” shall mean $                     per share, subject to adjustment pursuant to Section
4 below.

          (c) “Exercise Shares” shall mean the shares of Common Stock issuable upon exercise of this
Warrant.

          (d) “Trading Day” shall mean (i) any day on which the Common Stock is listed or quoted on its
primary trading market, (ii) if the Common Stock is not then listed or quoted and traded on any
eligible market (meaning any of the New York Stock Exchange, American Stock Exchange (“AMEX”) or
The NASDAQ Global Market), then a day on which trading occurs on the OTC Bulletin Board (or any
successor thereto), or (iii) if trading does not occur on the OTC Bulletin Board (or any successor
thereto), any business day.

     2. EXERCISE OF WARRANT. The rights represented by this Warrant may, subject to
Section 6 below, be exercised in whole or in part at any time during the Exercise Period, by
delivery of the following to the Company at its address set forth on the signature page hereto (or
at such other address as it may designate by notice in writing to the Holder):

          (a) An executed Notice of Exercise in the form attached hereto; and

 

 

          (b) Payment of the Exercise Price either in cash or by check (subject to the limitations in
Section 2.2 below.

     Execution and delivery of the Notice of Exercise shall have the same effect as cancellation of
the original Warrant and issuance of a new Warrant evidencing the right to purchase the remaining
number of Exercise Shares, if any. If requested by the Company, Holder agrees to provide this
Warrant, or an affidavit of lost security, to the Company within a reasonable period after the
delivery of the Notice of Exercise.

     Certificates for shares purchased hereunder shall be transmitted by the transfer agent of the
Company to the Holder by crediting the account of the Holder’s prime broker with the Depository
Trust Company through its Deposits and Withdrawal at Custodian (DWAC) system if the Company is a
participant in such system, and otherwise by physical delivery to the address specified by the
Holder in the Notice of Exercise within three business days from the delivery to the Company of the
Notice of Exercise, surrender of this Warrant and payment of the aggregate Exercise Price as set
forth above. This Warrant shall be deemed to have been exercised on the date the Exercise Price is
received by the Company. The Exercise Shares shall be deemed to have been issued, and Holder or
any other person so designated to be named therein shall be deemed to have become a holder of
record of such shares for all purposes, as of the date this Warrant has been exercised by payment
to the Company of the Exercise Price. If by the close of the third Trading Day after delivery of a
Notice of Exercise, the Company fails to deliver to the Holder a certificate representing the
required number of Exercise Shares in the manner required pursuant to this Section 2, and
such failure to deliver the Exercise Shares is caused by the Company’s failure to use commercially
reasonable efforts to comply with this Section 2 and/or the covenants in Section
3.1 herein, and if after such third Trading Day and prior to the receipt of such Exercise
Shares, the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to
deliver in satisfaction of a sale by the Holder of the Exercise Shares which the Holder anticipated
receiving upon such exercise (a “Buy-In”), then the Company shall, within three Trading Days after
the Holder’s request and in the Holder’s sole discretion, either (1) pay in cash to the Holder an
amount equal to the Holder’s total purchase price (including brokerage commissions, if any) for the
shares of Common Stock so purchased (the “Buy-In Price”), at which point the Company’s obligation
to deliver such certificate (and to issue such Exercise Shares) shall terminate or (ii) promptly
honor its obligation to deliver to the Holder a certificate or certificates representing such
Exercise Shares and pay cash to the Holder in an amount equal to the excess (if any) of the Buy-In
Price over the product of (a) such number of Exercise Shares, times (b) the closing bid price on
the date of the event giving rise to the Company’s obligation to deliver such certificate.

     The person in whose name any Exercise Shares are to be issued upon exercise of this Warrant
shall be deemed to have become the holder of record of such shares on the date on which this
Warrant was surrendered and payment of the Exercise Price was made, irrespective of the date of
delivery of such certificate or certificates, except that, if the date of such surrender and
payment is a date when the stock transfer books of the Company are closed, such person shall be
deemed to have become the holder of such shares at the close of business on the next succeeding
date on which the stock transfer books are open.

2

 

     To the extent permitted by law, the Company’s obligations to issue and deliver Exercise Shares
in accordance with the terms hereof are absolute and unconditional, irrespective of any action or
inaction by the Holder to enforce the same, any waiver or consent with respect to any provision
hereof, the recovery of any judgment against any person or entity or any action to enforce the
same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged
breach by the Holder or any other person or entity of any obligation to the Company or any
violation or alleged violation of law by the Holder or any other person or entity, and irrespective
of any other circumstance which might otherwise limit such obligation of the Company to the Holder
in connection with the issuance of Exercise Shares. Nothing herein shall limit a Holder’s right to
pursue any other remedies available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s
failure to timely deliver certificates representing shares of Common Stock upon exercise of this
Warrant as required pursuant to the terms hereof.

          2.2 ISSUANCE OF NEW WARRANTS. Upon any partial exercise of this Warrant, the Company,
at its expense, will forthwith and, in any event within five business days, issue and deliver to
the Holder a new warrant or warrants of like tenor, registered in the name of the Holder,
exercisable, in the aggregate, for the balance of the number of shares of Common Stock remaining
available for purchase under this Warrant.

          2.3 EXERCISE LIMITATIONS; HOLDER’S RESTRICTIONS. A Holder shall not have the right to
exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent
that after giving effect to such issuance after exercise, such Holder (together with such Holder’s
affiliates), as set forth on the applicable Notice of Exercise, would beneficially own in excess of
4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to
such issuance. For purposes of the foregoing sentence, the number of shares of Common Stock
beneficially owned by such Holder and its affiliates shall include the number of shares of Common
Stock issuable upon exercise of this Warrant with respect to which the determination of such
sentence is being made, but shall exclude the number of shares of Common Stock which would be
issuable upon (a) exercise of the remaining, non-exercised portion of this Warrant beneficially
owned by such Holder or any of its affiliates and (b) exercise or conversion of the unexercised or
non-converted portion of any other securities of the Company (including, without limitation, any
other shares of Common Stock or Warrants) subject to a limitation on conversion or exercise
analogous to the limitation contained herein beneficially owned by such Holder or any of its
affiliates. Except as set forth in the preceding sentence, for purposes of this Section
2.4, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange
Act, it being acknowledged by a Holder that the Company is not representing to such Holder that
such calculation is in compliance with Section 13(d) of the Exchange Act and such Holder is solely
responsible for any schedules required to be filed in accordance therewith. To the extent that the
limitation contained in this Section 2.4 applies, the determination of whether this Warrant
is exercisable (in relation to other securities owned by such Holder) and of which a portion of
this Warrant is exercisable shall be in the sole discretion of a Holder, and the submission of a
Notice of Exercise shall be deemed to be each Holder’s determination of whether this Warrant is
exercisable (in relation to other securities owned by such Holder) and of which portion of this
Warrant is exercisable, in each case subject to such aggregate percentage limitation, and the
Company shall have no obligation to verify or confirm the accuracy of such determination. For
purposes of this Section 2.4, in determining the number

3

 

of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares
of Common Stock as reflected in (x) the Company’s most recent Form 10-Q or Form 10-K, as the case
may be, (y) a more recent public announcement by the Company or (z) any other notice by the Company
or the Company’s Transfer Agent setting forth the number of shares of Common Stock outstanding.
Upon the written or oral request of a Holder, the Company shall within two Trading Days confirm
orally and in writing to such Holder the number of shares of Common Stock then outstanding. In any
case, the number of outstanding shares of Common Stock shall be determined after giving effect to
the conversion or exercise of securities of the Company, including this Warrant, by such Holder or
its affiliates since the date as of which such number of outstanding shares of Common Stock was
reported. The provisions of this Section 2.4 may be waived by such Holder, at the election
of such Holder, upon not less than 61 days’ prior notice to the Company to allow the Holder to
become the beneficial owner of not more than 9.99% of the Common Stock outstanding, and the
provisions of this Section 2.4 shall continue to apply until such 61st day (or such later
date, as determined by such Holder, as may be specified in such notice of waiver).

     3. COVENANTS
OF THE COMPANY. The Company covenants and agrees that all
Exercise Shares that may be issued upon the exercise of the rights represented by this Warrant
will, upon issuance, be validly issued and outstanding, fully paid and nonassessable, and free from
all taxes, liens and charges with respect to the issuance thereof. The Company further covenants
and agrees that the Company will at all times during the Exercise Period, have authorized and
reserved, free from preemptive rights, a sufficient number of shares of Common Stock to provide for
the exercise of the rights represented by this Warrant. If at any time during the Exercise Period
the number of authorized but unissued shares of Common Stock shall not be sufficient to permit
exercise of this Warrant, the Company will take such corporate action as may, in the opinion of its
counsel, be necessary to increase its authorized but unissued shares of Common Stock to such number
of shares as shall be sufficient for such purposes. The Company shall use commercially reasonable
efforts to keep a registration statement (a “Registration Statement”) with respect to the issuance
and sale of the Exercise Shares to the Holder, or such Holder’s valid assignee, in effect during
the Exercise Period or such shorter period that will terminate when this Warrant has been
exercised, and during such time period shall use commercially reasonable efforts to obtain the
prompt withdrawal of any stop order suspending the effectiveness of any such Registration
Statement. At any time during which the Exercise Shares are included in a then-effective
Registration Statement, the Company may suspend the ability of the Holder to exercise this Warrant
in any manner contemplated by this Warrant, for a reasonable period or periods (a “Black-out
Period”), in the event that (i)(a) an event occurs and is continuing as a result of which the
Registration Statement including the Exercise Shares, any related prospectus or any document
incorporated therein by reference as then amended or supplement would, in the Company’s good faith
judgment, contain an untrue statement of a material fact or omit to state a material fact necessary
in order to make the statements therein, in the light of the circumstances under which they were
made, not misleading, and (b) the Company determined in its good faith judgment that the disclosure
of such event at such time would be to the detriment of the business, operations or prospects of
the Company or the disclosure otherwise relates to a business transaction, operations or other
material event which has not yet been publicly disclosed, or (ii) the Registration

4

 

Statement is no longer effective and the holder is not permitted to sell Exercise Shares
pursuant to any other registration statement or an exemption to the registration requirements of
the Securities Act of 1933, as amended (the “Securities Act”); provided, however, that in the event
that a Black-out Period occurs subsequent to the one year anniversary of the Date of Issuance, this
Warrant shall be exercised subject to the terms and conditions of Section 4.
Notwithstanding the foregoing provisions of this Section 3.1, (i) if a Holder is not able
to exercise this Warrant because the Company has implemented a Black-out Period, then the Exercise
Period shall be extended for the number of calendar days covered by such Black-out Period and (ii)
the Company will use commercially reasonable efforts to ensure that the aggregate number of days
covered by Black-out Periods shall not last for more than twenty (20) consecutive days or exceed
sixty (60) in a particular calendar year; provided, however, that the holder may not receive any
penalties, cash payments or any other liquidated damages for failure to deliver registered Exercise
Shares so long as the Company has used commercially reasonable efforts to deliver the Holder the
Exercise Shares as contemplated in Section 2 herein or otherwise complies with the covenants in
this Section 3.1, and (c) if the Black-out Period is required because the Registration
Statement is no longer effective and the Holder is not permitted to sell Exercise Shares pursuant
to any other registration statement or an exemption to the registration requirements of the
Securities Act of 1933, then the Exercise Period shall be extended until such Holder may sell such
Exercise Shares.

     4. CASHLESS EXERCISE. If at any time there is no effective Registration Statement
registering, or no current prospectus available for, the resale of the Exercise Shares by the
Holder, then this Warrant may also be exercised at such time by means of a “cashless exercise” in
which the Holder shall be entitled to receive a certificate for the number of Exercise Shares equal
to the quotient obtained by dividing [(A-B) (X)] by (A), where:

	 	(A)	=  	 the VWAP on the Trading Day immediately preceding the date
of such election;
	 
	 	(B)	=	 the Exercise Price of this Warrant, as adjusted; and
	 
	 	(X)	=	 the number of Exercise Shares issuable upon exercise of this
Warrant in accordance with the terms of this Warrant by means of a cash
exercise rather than a cashless exercise.

“VWAP” means, for any date, the price determined by the first of the following clauses that
applies: (a) if the Common Stock is then listed or quoted on a trading market, the daily volume
weighted average price of the Common Stock for such date (or the nearest preceding date) on the
trading market on which the Common Stock is then listed or quoted for trading as reported by
Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York
City time); (b)  if the OTC Bulletin Board is not a trading market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on the OTC Bulletin Board;
(c) if the Common Stock is not then quoted for trading on the OTC Bulletin Board and if prices for
the Common Stock are then reported in the “Pink Sheets” published by Pink Sheets, LLC (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price
per share of the Common Stock so reported; or (d) in all other cases, the fair market value of a
share of Common Stock as determined by an independent

5

 

appraiser
selected in good faith by the purchasers of a majority in interest of
the shares of Common Stock issued in the Offering then
outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid
by the Company.

     5. NO IMPAIRMENT. Except and to the extent as waived or consented to by each holder
of Company Warrants, the Company will not, by amendment of its Certificate of Incorporation or
through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance
of any of the terms to be observed or performed hereunder by the Company, but will at all times in
good faith assist in the carrying out of all the provisions of this Warrant and in the taking of
all such action as may be necessary or appropriate in order to protect the exercise rights of the
Holder against impairment.

     6. ADJUSTMENT OF EXERCISE PRICE AND SHARES.

          (a) In the event of changes in the outstanding Common Stock of the Company by reason of stock
dividends, split-ups, recapitalizations, reclassifications, combinations or exchanges of shares,
separations, reorganizations, liquidations, consolidation, acquisition of the Company (whether
through merger or acquisition of substantially all the assets or stock of the Company), or the
like, the number, class and type of shares available under this Warrant in the aggregate and the
Exercise Price shall be correspondingly adjusted to give the Holder of this Warrant, on exercise
for the same aggregate Exercise Price, the total number, class, and type of shares or other
property as the Holder would have owned had this Warrant been exercised prior to the event and had
the Holder continued to hold such shares until the event requiring adjustment. The form of this
Warrant need not be changed because of any adjustment in the number of Exercise Shares subject to
this Warrant.

          (b) If at any time or from time to time the holders of Common Stock of the Company (or any
shares of stock or other securities at the time receivable upon the exercise of this Warrant) shall
have received or become entitled to receive, without payment therefor,

          (i) Common Stock or any shares of stock or other securities which are at any time
directly or indirectly convertible into or exchangeable for Common Stock, or any rights or
options to subscribe for, purchase or otherwise acquire any of the foregoing by way of
dividend or other distribution (other than a dividend or distribution covered in Section
4(a)  above);

          (ii) any cash paid or payable otherwise than as a cash dividend; or

          (iii) Common Stock or additional stock or other securities or property (including cash)
by way of spinoff, split-up, reclassification, combination of shares or similar corporate
rearrangement (other than shares of Common Stock pursuant to Section 4(a) above),

then and in each such case, the Holder hereof will, upon the exercise of this Warrant, be entitled
to receive, in addition to the number of shares of Common Stock receivable thereupon, and without
payment of any additional consideration therefor, the amount of stock and other securities and
property, as applicable, (including cash in the cases referred to in clauses (ii) and

6

 

(iii) above) which such Holder would hold on the date of such exercise had such Holder been the
holder of record of such Common Stock as of the date on which holders of Common Stock received or
became entitled to receive such shares or all other additional stock and other securities and
property.

          (c) Upon the occurrence of each adjustment pursuant to this Section 4, the Company at
its expense will, at the written request of the Holder, promptly compute such adjustment in
accordance with the terms of this Warrant and prepare a certificate setting forth such adjustment,
including a statement of the adjusted Exercise Price and adjusted number or type of Exercise Shares
or other securities issuable upon exercise of this Warrant (as applicable), describing the
transactions giving rise to such adjustments and showing in detail the facts upon which such
adjustment is based. Upon written request, the Company will promptly deliver a copy of each such
certificate to the Holder and to the Company’s transfer agent.

     7. FRACTIONAL SHARES. No fractional shares shall be issued upon the exercise of this
Warrant as a consequence of any adjustment pursuant hereto. All Exercise Shares (including
fractions) issuable upon exercise of this Warrant may be aggregated for purposes of determining
whether the exercise would result in the issuance of any fractional share. If, after aggregation,
the exercise would result in the issuance of a fractional share, the Company shall, in lieu of
issuance of any fractional share, pay the Holder otherwise entitled to such fraction a sum in cash
equal to the product resulting from multiplying the then current Fair Market Value of an Exercise
Share by such fraction. “Fair Market Value” of one share of Common Stock shall mean (i) the
average of the closing sales prices for the shares of Common Stock on AMEX or other trading market
where such security is listed or traded as reported by Bloomberg Financial Markets (or a comparable
reporting service of national reputation selected by the Company and reasonably acceptable to the
Holder if Bloomberg Financial Markets is not then reporting sales prices of such security)
(collectively, “Bloomberg”) for the ten (10) consecutive trading days immediately preceding such
date, or (ii) if AMEX is not the principal trading market for the shares of Common Stock, the
average of the reported sales prices reported by Bloomberg on the principal trading market for the
Common Stock during the same period, or, if there is no sales price for such period, the last sales
price reported by Bloomberg for such period, or (iii) if neither of the foregoing applies, the last
sales price of such security in the over-the-counter market on the pink sheets or bulletin board
for such security as reported by Bloomberg, or if no sales price is so reported for such security,
the last bid price of such security as reported by Bloomberg or (iv) if Fair Market Value cannot be
calculated as of such date on any of the foregoing bases, the Fair Market Value shall be as
determined by the Board of Directors of the Company in the exercise of its good faith judgment.

     8. FUNDAMENTAL TRANSACTIONS. If, at any time while this Warrant is outstanding,
(i) the Company effects any merger or consolidation of the Company with or into another entity, in
which the shareholders of the Company as of immediately prior to the transaction own less than a
majority of the outstanding stock of the surviving entity, (ii) the Company effects any sale of all
or substantially all of its assets in one or a series of related transactions, (iii) any tender
offer or exchange offer (whether by the Company or another person or entity) is completed pursuant
to which holders of Common Stock are permitted to tender or exchange their shares for other
securities, cash or property, or (iv) the Company effects any reclassification of the Common Stock
or any compulsory share exchange pursuant to which the

7

 

Common Stock is effectively converted into or exchanged for other securities, cash or property
(other than as a result of a subdivision or combination of shares of Common Stock covered by
Section 4 above) (each, a “Fundamental Transaction”), then the Holder shall have the right
thereafter to receive, upon exercise of this Warrant, the same amount and kind of securities, cash
or property, as applicable, as it would have been entitled to receive upon the occurrence of such
Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the
holder of the number of Exercise Shares then issuable upon exercise in full of this Warrant (the
“Alternate Consideration”). Following any transaction contemplated by this Section 6, the
term Exercise Shares shall be deemed to refer to the shares for which this Warrant is thereafter
exercisable in accordance with the provisions hereof. In addition, if holders of Common Stock are
given a choice as to the securities, cash (which shall be treated in accordance with the preceding
paragraph) or property to be received in a Fundamental Transaction (including a right to elect to
receive any particular one or combination of more than one of the foregoing), then the Holder shall
be given the same choice of consideration upon any exercise of this Warrant following such
Fundamental Transaction, which choice of consideration can be made at the time of exercise at any
time prior to the expiration of the Exercise Period.

     9. NO STOCKHOLDER RIGHTS. Other than as provided in Section 3.3 or otherwise
herein, this Warrant in and of itself shall not entitle the Holder to any voting rights or other
rights as a stockholder of the Company.

     10. TRANSFER OF WARRANT. Subject to compliance with any applicable laws, this Warrant
and all rights hereunder are transferable, by the Holder in person or by duly authorized attorney,
upon delivery of this Warrant and the form of assignment attached hereto to any transferee
designated by the Holder. For a period of six months after the issuance date of this Warrant
(which shall not be earlier than the closing date of the offering pursuant to which this Warrant is
being issued), neither this Warrant nor any Warrant Shares issued upon exercise of this Warrant
shall be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging,
short sale, derivative, put, or call transaction that would result in the effective economic
disposition of the securities by any person for a period of 180 days immediately following the date
of effectiveness or commencement of sales of the offering pursuant to which this Warrant is being
issued, except the transfer of any security:

(i) by operation of law or by reason of reorganization of the Company;

(ii) to any FINRA member firm participating in the offering and the officers or partners thereof,
if all securities so transferred remain subject to the lock-up restriction in this Section 10 for
the remainder of the time period;

(iii) if the aggregate amount of securities of the Company held by the Holder or related person do
not exceed 1% of the securities being offered;

(iv) that is beneficially owned on a pro-rata basis by all equity owners of an investment fund,
provided that no participating member manages or otherwise directs investments by the fund, and
participating members in the aggregate do not own more than 10% of the equity in the fund; or

8

 

(v) the exercise or conversion of any security, if all securities received remain subject to the
lock-up restriction in this Section 10 for the remainder of the time period.

     11. LOST, STOLEN, MUTILATED OR DESTROYED WARRANT. If this Warrant is lost, stolen,
mutilated or destroyed, the Company may, on such terms as to indemnity or otherwise as it may
reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender thereof),
issue a new Warrant of like denomination and tenor as this Warrant so lost, stolen, mutilated or
destroyed. Any such new Warrant shall constitute an original contractual obligation of the
Company, whether or not the allegedly lost, stolen, mutilated or destroyed Warrant shall be at any
time enforceable by anyone.

     12. NOTICES, ETC. All notices required or permitted hereunder shall be in writing and
shall be deemed effectively given: (a) upon personal delivery to the party to be notified,
(b) when sent by confirmed telex, electronic transmission or facsimile if sent during normal
business hours of the recipient, if not, then on the next business day, (c) five days after having
been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one
day after deposit with a nationally recognized overnight courier, specifying next day delivery,
with written verification of receipt. All communications shall be sent to the Company at the
address listed on the signature page hereto and to the Holder at the applicable address set forth
on the applicable signature page to the Subscription Agreement or at such other address as the
Company or the Holder may designate by ten (10) days advance written notice to the other parties
hereto.

     13. ACCEPTANCE. Receipt of this Warrant by the Holder shall constitute acceptance of
and agreement to all of the terms and conditions contained herein.

     14. GOVERNING LAW. This Warrant shall be governed by, and construed in accordance
with, the laws of the State of New York. The Holder hereby submits to the non-exclusive
jurisdiction of the Federal and state courts in the Borough of Manhattan in The City of New York in
any suit or proceeding arising out of or relating to this Agreement or the transactions
contemplated thereby. The Holder irrevocably and unconditionally waives any objection to the
laying of venue of any suit or proceeding arising out of or relating to this Warrant in Federal and
state courts in the Borough of Manhattan in The City of New York and irrevocably and
unconditionally waives and agrees not to plead or claim in any such court that any such suit or
proceeding in any such court has been brought in an inconvenient forum.

     15. AMENDMENT OR WAIVER. Any term of this Warrant may be amended or waived (either generally
or in a particular instance and either retroactively or prospectively) with the written consent of
the Company and the holders of Company Warrants representing at least two-thirds of the number of
shares of Common Stock then subject to outstanding Company Warrants, except that the amendment or
waiver of any provision of Sections 4 or 8 shall require the written consent of the Company and the
holders of Company Warrants representing at least 90% of the number of shares of Common Stock then
subject to outstanding Company Warrants. Notwithstanding the foregoing, (a) this Warrant may be
amended and the observance of any term hereunder may be waived without the written consent of the
Holder only in a manner which applies to all Company Warrants in the same fashion and (b) the
number of Exercise Shares subject to this Warrant and the Exercise Price of this Warrant may not be
amended, and the right

9

 

to exercise this Warrant may not be waived, without the written consent of the Holder. The
Company shall give prompt written notice to the Holder of any amendment hereof or waiver hereunder
that was effected without the Holder’s written consent. No waivers of any term, condition or
provision of this Warrant, in any one or more instances, shall be deemed to be, or construed as, a
further or continuing waiver of any such term, condition or provision.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

10

 

     IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its duly authorized
officer as of _______, 2008.

	 	 	 	 	 
	 	POLYMEDIX, INC.
	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 

170 N. Radnor-Chester Road

Suite 300

Radnor, Pennsylvania 19087

11

 

NOTICE OF EXERCISE

TO: POLYMEDIX, INC.

     (1) The undersigned hereby elects to purchase [                    ] shares of the common stock, par
value $0.001 (the “Common Stock”), of POLYMEDIX, INC. (the “Company”) pursuant to the terms of the
attached Warrant, and tenders herewith payment of the exercise price in full, together with all
applicable transfer taxes, if any, subject to the limitations set forth in Section 2.1 of
the Warrant.

     (2) Please issue the certificate for shares of Common Stock in the name of, and pay any cash
for any fractional share to:

 

Print or type name

 

Social Security or other Identifying Number

 

Street Address

 

City, State, Zip Code

     (3) If such number of shares shall not be all the shares purchasable upon the exercise of the
Warrants evidenced by this Warrant, a new warrant certificate for the balance of such Warrants
remaining unexercised shall be registered in the name of and delivered to:

     Please insert Social Security or other identifying number:                                         

(Please print name and address)

	 	 	 	 	 	 	 	 	 
	Dated:
	 	 	 	 	 	 	 	 
	 

	 	 

(Date)
	 	 	 	 

(Signature)
	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 

(Print Name)
	 	 

 

 

ASSIGNMENT FORM

     (To assign the foregoing Warrant, execute this form and supply required information. Do not
use this form to purchase shares.)

     FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned
to

	 	 	 	 	 	 	 	 
	 

	 	Name:	 	 	 	 	 
	 

	 	 	 	 

(Please Print)
	 	 
	 
	 	 	 	 	 	 	 
	 

	 	Address:	 	 	 	 	 
	 

	 	 	 	 

(Please Print)
	 	 
	 
	 	 	 	 	 	 	 
	 

	 	Dated:
	 	 
	, 200__	 	 
	 
	 	 	 	 	 	 	 
	 

	 	Holder’s Signature:	 	 	 	 	 
	 

	 	 	 	 

	 	 
	 
	 	 	 	 	 	 	 
	 

	 	Holder’s Address:	 	 	 	 	 
	 

	 	 	 	 

	 	 

NOTE: The signature to this Assignment Form must correspond with the name as it appears on the
face of the Warrant, without alteration or enlargement or any change whatever. Officers of
corporations and those acting in a fiduciary or other representative capacity should file proper
evidence of authority to assign the foregoing Warrant.exv10w21

AMENDED
AND RESTATED
CO-PLACEMENT AGENT AGREEMENT

June 27, 2008

Carter Securities LLC

725 Fifth Avenue, 24th Floor

New York, NY 10022

Fordham Financial Management, Inc.

14 Wall Street, 18th Floor

New York, NY 10005

Dear Sirs:

     1. Introductory. PolyMedix Inc., a Delaware corporation (the “Company”) is
offering (the “Offering”) up to $15 million of
Units, subject to any agreed upon increase in compliance with
Rule 462(b)(3) under the Securities Act of 1933, as amended (the
“Securities Act”) (the “Units”), each consisting
of one share of the class of common stock of the Company (the “Shares”) and a warrant,
exercisable for approximately five years, to purchase one share of the class of common stock of the Company (the
“Warrants” and together with the Shares, the “Securities”), in an offering at a
purchase price per Unit to be determined after the date hereof by discussions between us. Carter
Securities LLC and Fordham Financial Management, Inc. will market the Units on the terms described
in the Base Prospectus and any Prospectus Supplement (as such terms are hereinafter defined) as
co-placement agents (the “Placement Agents”) on a “best-efforts” basis. Each Placement
Agent agrees that it will use its reasonable efforts to assist the Company in identifying,
evaluating and approaching prospective purchasers of the Units but each Placement Agent disclaims
any agreement, expressed or implied, in this Co-Placement Agent Agreement (the “Agreement”)
or otherwise, that it will be successful in placing the Units. Notwithstanding anything in this
Agreement to the contrary, the Company shall have the sole and absolute discretion to accept or not
accept, in whole or in part, the terms of any subscription for Units. Prior to filing the
Registration Statement, the Company will obtain the approval of the Placement Agents as to the
anticipated price range of the Unit offering and warrant exercise
price. This Agreement amends and restates in its entirety the
Co-Placement Agent Agreement dated May 21, 2008.

     2. Registration Statement. The Company represents and warrants to each of the
Placement Agents and each sub-placement agent and/or selected dealer, if any, and agrees with each
such person (collectively, the “Agents”) that:

     (a) The Company will, promptly after the date hereof, file with the Securities and Exchange
Commission (the “Commission”) a registration statement on Form S-1 under the Securities Act, for the registration under the Securities Act
of the Units and the Securities. At the time of such filing, the Company met the requirements of
Form S-1 under the Securities Act. Such registration statement will meet the requirements set
forth in Rule 430A under the Securities Act and comply with said Rules. The Company will file with
the Commission pursuant to Rule 424(b) under the Securities Act, and the rules and regulations of
the Commission promulgated thereunder (the “Rules and Regulations”), a supplement to the
form of prospectus included in such registration statement relating to the placement of the Units
and the plan of distribution thereof and such other information as may have been omitted from the
Base Prospectus in compliance with Rule 430A and has advised the Placement Agents of all further
information (financial and other) with respect to the Company required to be set forth therein.
Such registration statement, including the exhibits thereto, as filed with the Commission, is
hereinafter called the “Registration Statement”; such prospectus in the form in which it
appears in the Registration Statement is hereinafter called the “Base Prospectus”; and the
supplemented form of prospectus, in the form in which it will be filed with the Commission pursuant
to Rule 424(b) (including

-1-

 

the Base Prospectus as so supplemented) is hereinafter called the “Prospectus
Supplement.” No stop order suspending the effectiveness of the Registration Statement or the
use of the Base Prospectus or the Prospectus Supplement has been issued, and no proceeding for any
such purpose is pending or has been initiated or, to the knowledge of the chief executive officer
and chief financial officer of the Company (“Knowledge”), is threatened by the Commission.

     (b) The Registration Statement (and any further documents to be filed with the Commission)
will contain all exhibits and schedules as required by the Securities Act. The Registration
Statement will comply in all material respects with the Securities Act and the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), and the applicable Rules and Regulations, and
the Registration Statement, as amended or supplemented, if applicable, will not, contain any untrue
statement of a material fact or omit to state a material fact required to be stated therein or
necessary to make the statements therein, in light of the circumstances under which they were made,
not misleading. The Base Prospectus, and each Prospectus Supplement, each as of its respective
date, will comply in all material respects with the Securities Act and the Exchange Act and the
applicable Rules and Regulations. Each of the Base Prospectus and the Prospectus Supplement, as
amended or supplemented, will not contain as of the date thereof any untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein, in light
of the circumstances under which they were made, not misleading. There are no documents required
to be filed with the Commission in connection with the transaction contemplated hereby that (x)
have not been filed as required pursuant to the Securities Act or (y) will not be filed within the
requisite time period.

     (c) If the Company is not eligible to use free writing prospectuses in connection with the
Offering pursuant to Rules 164 and 433 under the Securities Act, the Company will not prepare, use
or refer to, any free writing prospectus.

     (d) The Company will deliver, as promptly as practicable, to the Placement Agents complete
conformed copies of the Registration Statement and of each consent and certificate of experts, as
applicable, filed as a part thereof, and conformed copies of the Registration Statement (without
exhibits), the Base Prospectus and the Prospectus Supplement, as amended or supplemented, in such
quantities and at such places as the Placement Agent reasonably requests. Neither the Company nor
any of its directors and officers has distributed and none of them will distribute, prior to the
final Closing Date of Offering, any offering material in connection with the offering and sale of
the Units other than the Base Prospectus, the Prospectus Supplement, the Registration Statement,
copies of the documents incorporated by reference therein and any other materials permitted by the
Securities Act.

     3. Representations and Warranties of the Company. Except as set forth in the
Registration Statement, the Company hereby makes the representations and warranties set forth below
to each of the Agents:

     (a) Organization and Qualification. All of the direct and indirect subsidiaries
(individually, a “Subsidiary”) of the Company are set forth in the Registration Statement.
The Company owns, directly or indirectly, all of the capital stock or other equity interests of
each Subsidiary free and clear of any “Liens” (which for purposes of this Agreement shall
mean a lien, charge, security interest, encumbrance, right of first refusal, preemptive right or
other restriction), and all the issued and outstanding shares of capital stock of each Subsidiary
are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to
subscribe for or purchase securities. The Company and each of the Subsidiaries is an entity
incorporated or otherwise organized, validly existing and in good standing under the laws of the
jurisdiction of its incorporation or organization (as applicable), with the requisite corporate
power and authority to own and use its properties and assets and to carry on its business as
currently conducted. Neither the Company nor any Subsidiary is in violation or default of any of
the provisions of its respective certificate or articles of

-2-

 

incorporation, bylaws or other organizational or charter documents. Each of the Company and
the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign
corporation or other entity in each jurisdiction in which the nature of the business conducted or
property owned by it makes such qualification necessary, except where the failure to be so
qualified or in good standing, as the case may be, could not have or reasonably be expected to
result in (i) a material adverse effect on the legality, validity or enforceability of this
Agreement or any subscription agreement or Warrant made with any Purchaser (together with the
Agreement, the “Transaction Documents”), (ii) a material adverse effect on the results of
operations, assets, business, prospects or condition (financial or otherwise) of the Company and
the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company’s ability to
perform in any material respect its obligations under any Transaction Document (any of (i), (ii) or
(iii), a “Material Adverse Effect”) and no “Proceeding” (which for purposes of this
Agreement shall mean any action, claim, suit, investigation or proceeding (including, without
limitation, an investigation or partial proceeding, such as a deposition), whether commenced or
threatened in writing) has been instituted in any such jurisdiction revoking, limiting or
curtailing or seeking to revoke, limit or curtail such power and authority or qualification.

     (b) Authorization; Enforcement. The Company has the requisite corporate power and
authority to enter into and to consummate the transactions contemplated by each of the Transaction
Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and
delivery of each of the Transaction Documents by the Company and the consummation by it of the
transactions contemplated thereby have been duly authorized by all necessary action on the part of
the Company and no further action is required by the Company, its board of directors or its
stockholders in connection therewith other than in connection with the Required Approvals (as
defined in subsection 3(d) below). Each Transaction Document has been (or upon delivery will have
been) duly executed by the Company and, when delivered in accordance with the terms thereof, will
constitute the valid and binding obligation of the Company enforceable against the Company in
accordance with its terms except (i) as limited by applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting enforcement of
creditors’ rights generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies, and (iii) as enforceability of the
indemnity and contribution provisions contained in Section 7 hereof may be limited by applicable
law or principles of public policy.

     (c) No Conflicts. The execution, delivery and performance of the Transaction
Documents by the Company, the issuance and sale of the Securities and the consummation by the
Company of the other transactions contemplated hereby and thereby do not and will not (i) conflict
with or violate any provision of the Company’s or any Subsidiary’s certificate or articles of
incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or
constitute a default (or an event that with notice or lapse of time or both would become a default)
under, result in the creation of any Lien upon any of the properties or assets of the Company or
any Subsidiary, or give to others any rights of termination, amendment, acceleration or
cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility,
debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other
understanding to which the Company or any Subsidiary is a party or by which any property or asset
of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals,
conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction,
decree or other restriction of any court or governmental authority to which the Company or a
Subsidiary is subject (including federal and state securities laws and regulations), or by which
any property or asset of the Company or a Subsidiary is bound or affected; except in the case of
each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a
Material Adverse Effect.

     (d) Filings, Consents and Approvals. The Company is not required to obtain any
consent, waiver, authorization or order of, give any notice to, or make any filing or registration
with, any court or other federal, state, local or other governmental authority or other
“Person” (defined as an individual or corporation, partnership, trust, incorporated or
unincorporated association, joint venture, limited liability company, joint

-3-

 

stock company, government (or an agency or subdivision thereof) or other entity of any kind,
including, without limitation, any Trading Market (as defined below)) in connection with the
execution, delivery and performance by the Company of the Transaction Documents, other than such
filings as are required to be made under applicable federal and state securities laws
(collectively, the “Required Approvals”).

     (e) Issuance of the Securities; Registration. The Securities are duly authorized and,
when issued and paid for in accordance with the applicable Transaction Documents, will be duly and
validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company
other than restrictions on transfer provided for in the Transaction Documents. The Company has
reserved from its duly authorized capital stock the maximum number of shares of its class of common
stock (the “Common Stock”) issuable pursuant to the Transaction Documents. The Common Stock
is the only class of common stock authorized by the Company’s Certificate of Incorporation. As of
the Closing Date, the issuance by the Company of the Securities will be registered under the
Securities Act and all of the Shares will be freely transferable and tradable by the persons
subscribing for the Units (the “Purchasers”) without
restriction (other than any restrictions arising solely from an act or omission of a Purchaser).
The Securities are being issued pursuant to the Registration Statement and the issuance of the
Securities has been registered by the Company under the Securities Act. As of the Closing Date,
the Registration Statement will be effective and available for the issuance of the Securities
thereunder and the Company will not have received any notice that the Commission has issued or
intends to issue a stop-order with respect to the Registration Statement or that the Commission
otherwise has suspended or withdrawn the effectiveness of the Registration Statement, either
temporarily or permanently, or intends or has threatened in writing to do so. The “Plan of
Distribution” section in the Registration Statement describes the issuance and sale of the
Securities hereunder. Upon receipt of the Securities, the Purchasers will have good and marketable
title to such Securities and the Shares will be freely tradable on the “Trading Market”
(which, for purposes of this Agreement shall mean the OTC Bulletin Board).

     (f) Capitalization. The capitalization of the Company is as set forth in the
Registration Statement. The Company has not issued any capital stock since its most recently filed
periodic report under the Exchange Act, other than pursuant to the exercise of employee stock
options under the Company’s stock option plans, the issuance of shares of Common Stock to employees
pursuant to the Company’s employee stock purchase plan and pursuant to the conversion or exercise
of securities exercisable, exchangeable or convertible into Common Stock (“Common Stock
Equivalents”). No Person has any right of first refusal, preemptive right, right of
participation, or any similar right to participate in the transactions contemplated by the
Transaction Documents. Except as a result of the purchase and sale of the Securities, there are no
outstanding options, warrants, script rights to subscribe to, calls or commitments of any character
whatsoever relating to, or securities, rights or obligations convertible into or exercisable or
exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common
Stock, or contracts, commitments, understandings or arrangements by which the Company or any
Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock
Equivalents. The issuance and sale of the Securities will not obligate the Company to issue shares
of Common Stock or other securities to any Person (other than the Purchasers) and will not result
in a right of any holder of Company securities to adjust the exercise, conversion, exchange or
reset price under such securities. All of the outstanding shares of capital stock of the Company
are validly issued, fully paid and nonassessable, have been issued in compliance with all federal
and state securities laws, and none of such outstanding shares was issued in violation of any
preemptive rights or similar rights to subscribe for or purchase securities. No further approval
or authorization of any stockholder, the board of directors of the Company or others is required
for the issuance and sale of the Securities. There are no stockholders agreements, voting
agreements or other similar agreements with respect to the Company’s capital stock to which the
Company is a party or, to the Knowledge of the Company, between or among any of the Company’s
stockholders.

-4-

 

     (g) SEC Reports; Financial Statements. The Company has complied in all material
respects with requirements to file all reports, schedules, forms, statements and other documents
required to be filed by it under the Securities Act and the Exchange Act, including pursuant to
Section 13(a) or 15(d) thereof, for the two years preceding the date hereof (or such shorter period
as the Company was required by law to file such material) (the foregoing materials, including the
exhibits thereto and documents incorporated by reference therein, being collectively referred to
herein as the “SEC Reports”) on a timely basis or has received a valid extension of such
time of filing and has filed any such SEC Reports prior to the expiration of any such extension.
As of their respective dates, the SEC Reports complied in all material respects with the
requirements of the Securities Act and the Exchange Act and the rules and regulations of the
Commission promulgated thereunder, and none of the SEC Reports, when filed, contained any untrue
statement of a material fact or omitted to state a material fact required to be stated therein or
necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading. The financial statements of the Company included in the SEC
Reports and in the Base Prospectus comply in all material respects with applicable accounting
requirements and the rules and regulations of the Commission with respect thereto as in effect at
the time of filing. Such financial statements have been prepared in accordance with United States
generally accepted accounting principles applied on a consistent basis during the periods involved
(“GAAP”), except as may be otherwise specified in such financial statements or the notes
thereto and except that unaudited financial statements may not contain all footnotes required by
GAAP, and fairly present in all material respects the financial position of the Company and its
consolidated subsidiaries as of and for the dates thereof and the results of operations and cash
flows for the periods then ended, subject, in the case of unaudited statements, to normal year-end
audit adjustments.

     (h) Material Changes; Undisclosed Events, Liabilities or Developments. Since the date
of the latest audited financial statements included within the Base Prospectus, except as
specifically disclosed in the Base Prospectus, (i) there has been no event, occurrence or
development that has had or that could reasonably be expected to result in a Material Adverse
Effect, (ii) the Company has not incurred any material liabilities (contingent or otherwise) other
than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent
with past practice and (B) liabilities not required to be reflected in the Company’s financial
statements pursuant to GAAP or required to be disclosed in filings made with the Commission, (iii)
the Company has not materially altered its method of accounting, (iv) the Company has not declared
or made any dividend or distribution of cash or other property to its stockholders or purchased,
redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) the
Company has not issued any equity securities to any officer, director or “Affiliate”
(defined as any Person that, directly or indirectly through one or more intermediaries, controls or
is controlled by or is under common control with a Person, as such terms are used in and construed
under Rule 144 under the Securities Act), except pursuant to existing Company equity compensation
plans. The Company does not have pending before the Commission any request for confidential
treatment of information. Except for the issuance of the Securities contemplated by this Agreement
or as set forth on Schedule 3(h), no material event, liability or development has occurred or
exists with respect to the Company or its Subsidiaries or their respective business, properties,
operations or financial condition, that would be required to be disclosed by the Company under
applicable securities laws at the time this representation is made that has not been publicly
disclosed one (1) trading day (any day on which the New York Stock Exchange is open for business)
prior to the date that this representation is made.

     (i) Litigation. There is no Proceeding, inquiry, or notice of violation pending or,
to the Knowledge of the Company, threatened in writing against or affecting the Company, any
Subsidiary or any of their respective properties before or by any court, arbitrator, governmental
or administrative agency or regulatory authority (federal, state, county, local or foreign)
(collectively, an “Action”) which (i) adversely affects or challenges the legality,
validity or enforceability of any of the Transaction Documents or the Securities or (ii) could, if
there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse
Effect. Neither the Company nor any Subsidiary, nor any director or officer thereof, is or has
been the subject of any Action involving a claim of violation of or liability under federal or
state securities

-5-

 

laws or a claim of breach of fiduciary duty. There has not been, and to the Knowledge of the
Company, there is not pending or contemplated, any investigation by the Commission involving the
Company or any current or former director or officer of the Company. The Commission has not issued
any stop order or other order suspending the effectiveness of any registration statement filed by
the Company or any Subsidiary under the Exchange Act or the Securities Act. None of the Company’s
or its Subsidiaries’ employees is a member of a union that relates to such employee’s relationship
with the Company, and neither the Company or any of its Subsidiaries is a party to a collective
bargaining agreement, and the Company and its Subsidiaries believe that their relationships with
their employees are good. No executive officer, to the Knowledge of the Company, is, or is now
expected to be, in violation of any material term of any employment contract, confidentiality,
disclosure or proprietary information agreement or non-competition agreement, or any other contract
or agreement or any restrictive covenant, and the continued employment of each such executive
officer does not subject the Company or any of its Subsidiaries to any liability with respect to
any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S.
federal, state, local and foreign laws and regulations relating to employment and employment
practices, terms and conditions of employment and wages and hours, except where the failure to be
in compliance could not, individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect.

     (j) Labor Relations. No material labor dispute exists or, to the Knowledge of the
Company, is imminent with respect to any of the employees of the Company which could reasonably be
expected to result in a Material Adverse Effect.

     (k) Compliance. Neither the Company nor any Subsidiary (i) is in default under or in
violation of (and no event has occurred that has not been waived that, with notice or lapse of time
or both, would result in a default by the Company or any Subsidiary under), nor has the Company or
any Subsidiary received notice of a claim that it is in default under or that it is in violation
of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a
party or by which it or any of its properties is bound (whether or not such default or violation
has been waived), (ii) is in violation of any order of any court, arbitrator or governmental body,
or (iii) is or has been in violation of any statute, rule or regulation of any governmental
authority, including without limitation all foreign, federal, state and local laws applicable to
its business and all such laws that affect the environment, except in each case as could not have a
Material Adverse Effect.

     (l) Regulatory Permits. The Company and the Subsidiaries possess all certificates,
authorizations and permits issued by the appropriate federal, state, local or foreign regulatory
authorities necessary to conduct their respective businesses as described in the Base Prospectus,
except where the failure to possess such permits could not have or reasonably be expected to result
in a Material Adverse Effect (“Material Permits”), and neither the Company nor any
Subsidiary has received any notice of proceedings relating to the revocation or modification of any
Material Permit.

     (m) Title to Assets. The Company and the Subsidiaries have good and marketable title
in fee simple to all real property owned by them that is material to the business of the Company
and the Subsidiaries and good and marketable title in all personal property owned by them that is
material to the business of the Company and the Subsidiaries, in each case free and clear of all
Liens, except for Liens as do not materially affect the value of such property and do not
materially interfere with the use made of such property by the Company and the Subsidiaries and
Liens for the payment of federal, state or other taxes, the payment of which is neither delinquent
nor subject to penalties. Any real property and facilities held under lease by the Company and the
Subsidiaries are held by them under valid, subsisting and enforceable leases of which the Company
and the Subsidiaries are in compliance.

     (n) Patents and Trademarks. The Company and the Subsidiaries have, or have rights to
use, all patents, patent applications, trademarks, trademark applications, service marks, trade
names, trade secrets, inventions, copyrights, licenses and other similar intellectual property
rights necessary or material for use in

-6-

 

connection with their respective businesses as described in the Base Prospectus and which the
failure to so have could have a Material Adverse Effect (collectively, the “Intellectual
Property Rights”). Neither the Company nor any Subsidiary has received a written notice that
the Intellectual Property Rights used by the Company or any Subsidiary violates or infringes upon
the rights of any Person. To the Knowledge of the Company, all such Intellectual Property Rights
are enforceable and there is no existing infringement by another Person of any of the Intellectual
Property Rights of others. The Company and its Subsidiaries have taken reasonable security
measures to protect the secrecy, confidentiality and value of all of their Intellectual Property
Rights, except where failure to do so could not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect.

     (o) Insurance. The Company and the Subsidiaries are insured by such insurers, against
such losses and risks, and in such amounts as are prudent and customary in the businesses in which
the Company and the Subsidiaries are engaged, including, but not limited to, directors and officers
insurance coverage of up to $10 million. Neither the Company nor any Subsidiary has any reason to
believe that it will not be able to renew its existing insurance coverage as and when such coverage
expires or to obtain similar coverage from similar insurers as may be necessary to continue its
business without a significant increase in cost.

     (p) Transactions with Affiliates and Employees. Except as set forth in the Base
Prospectus, none of the officers or directors of the Company and, to the Knowledge of the Company,
none of the employees of the Company is presently a party to any transaction with the Company or
any Subsidiary (other than for services as employees, officers and directors), including any
contract, agreement or other arrangement providing for the furnishing of services to or by,
providing for rental of real or personal property to or from, or otherwise requiring payments to or
from any officer, director or such employee or, to the Knowledge of the Company, any entity in
which any officer, director, or any such employee has a substantial interest or is an officer,
director, trustee or partner, other than (i) for payment of salary or consulting or director fees
for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii)
for other employee benefits, including stock option or other agreements under any equity
compensation plan of the Company.

     (q) Sarbanes-Oxley. The Company is in material compliance with all provisions of the
Sarbanes-Oxley Act of 2002 which are applicable to it as of the date hereof and of each Closing
Date (if more than one) (as herein defined in Section 5(b)) of the Offering.

     (r) Certain Fees. Except as otherwise provided in this Agreement, no brokerage or
finder’s fees or commissions are or will be payable by the Company to any broker, financial advisor
or consultant, finder, placement agent, investment banker, bank or other person with respect to the
transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation
with respect to any fees or with respect to any claims made by or on behalf of other Persons for
fees of a type contemplated in this Section that may be due in connection with the transactions
contemplated by the Transaction Documents as a result of the actions of the Company.

     (s) Trading Market Rules. The issuance and sale of the Securities hereunder does not
contravene the rules and regulations of the OTC Bulletin Board.

     (t) Investment Company. The Company is not, and is not an Affiliate of, and
immediately after receipt of payment for the Securities, will not be or be an Affiliate of, an
“investment company” within the meaning of the Investment Company Act of 1940, as amended. The
Company shall conduct its business in a manner so that it will not become subject to the Investment
Company Act.

     (u) Registration Rights. No Person has any right to cause the Company to effect the
registration under the Securities Act of any securities of the Company.

-7-

 

     (v) Listing and Maintenance Requirements. The Company’s Common Stock is registered
pursuant to Section 12(g) of the Exchange Act, and the Company has taken no action designed to, or
which to its Knowledge is likely to have the effect of, terminating the registration of the Common
Stock under the Exchange Act nor has the Company received any notification that the Commission is
contemplating terminating such registration. The Company has not, in the 12 months preceding the
date hereof, received notice from the Trading Market to the effect that the Company is not eligible
for quotation on the Trading Market or that the Common Stock will be removed from the Trading
Market.

     (w) Application of Takeover Protections. The Company and its board of directors have
taken all necessary action, if any, in order to render inapplicable any control share acquisition,
business combination, poison pill (including any distribution under a rights agreement) or other
similar anti-takeover provision under the Company’s Certificate of Incorporation (or similar
charter documents) or the laws of its state of incorporation that is or could become applicable to
the Purchasers as a result of the Purchasers and the Company fulfilling their obligations or
exercising their rights under the Transaction Documents, including without limitation as a result
of the Company’s issuance of the Securities and the Purchasers’ ownership of the Securities.

     (x) Solvency. The Company does not intend to incur debts beyond its ability to pay
debts as they mature (taking into account the timing and amounts of cash to be payable on or in
respect of its debt). The Company has no Knowledge of any facts or circumstances which lead it to
believe that it will file for reorganization or liquidation under the bankruptcy or reorganization
laws of any jurisdiction within one year from the Closing Date. The SEC Reports set forth as of
the dates thereof all outstanding secured and unsecured Indebtedness of the Company or any
Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes of this
Agreement, “Indebtedness” shall mean (a) any liabilities for borrowed money or amounts owed
in excess of $50,000 (other than trade accounts payable incurred in the ordinary course of
business), (b) all guaranties, endorsements and other contingent obligations in respect of
Indebtedness of others, whether or not the same are or should be reflected in the Company’s balance
sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for
deposit or collection or similar transactions in the ordinary course of business; and (c) the
present value of any lease payments in excess of $50,000 due under leases required to be
capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with
respect to any Indebtedness.

     (y) Tax Status. Except for matters that would not, individually or in the aggregate,
have or reasonably be expected to result in a Material Adverse Effect, the Company and each
Subsidiary has filed all necessary federal, state and foreign income and franchise tax returns and
has paid or accrued all taxes shown as due thereon, and the Company has no Knowledge of a tax
deficiency which has been asserted or threatened against the Company or any Subsidiary.

     (z) Foreign Corrupt Practices. Neither the Company, nor to the Knowledge of the
Company, any agent or other person acting on behalf of the Company, has (i) directly or indirectly,
used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related
to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic
government officials or employees or to any foreign or domestic political parties or campaigns from
corporate funds, (iii) failed to disclose fully any contribution made by the Company (or made by
any person acting on its behalf of which the Company is aware) which is in violation of law, or
(iv) violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977,
as amended.

     (aa) Regulation M Compliance. The Company has not, and to its Knowledge no one acting
on its behalf has, during the Offering, (i) taken, directly or indirectly, any action designed to
cause or to result in the stabilization or manipulation of the price of any security of the Company
to facilitate the sale or resale of any

-8-

 

of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting
purchases of, any of the Securities (other than as set forth herein), or (iii) paid or agreed to
pay to any person any compensation for soliciting another to purchase any other securities of the
Company.

     (bb) FINRA Affiliations. There are no affiliations with any Financial Industry
Regulatory Authority (“FINRA”) member firm among the Company’s officers, directors or, to
the Knowledge of the Company, any five percent (5%) or greater stockholder of the Company.

     4. Representations, Warranties and Covenants of the Placement Agents. Each Placement
Agent, severally and not jointly, represents and warrants to, and agrees with, the Company that:

     (a) the Placement Agent is duly organized and is validly existing and in good standing as a
limited liability company or a corporation under the laws of its state of organization, with power
and authority to perform its obligations under this Agreement; it is a broker-dealer registered and
in good standing under the Exchange Act and under the securities or “blue sky” laws of each state
in which the Units are being offered or sold by it, and it is a member in good standing of the
FINRA and will comply with FINRA Conduct Rule 2740 and all other applicable federal or state
securities laws and FINRA rules and regulations.

     (b) the Placement Agent has received the representations and warranties of each of the Agents
that such Agent is (a) a member in good standing of the FINRA and will comply with FINRA Conduct
Rule 2740 and all other applicable federal or state securities laws and FINRA rules and
regulations, or (b) a foreign dealer or institution that is not eligible for membership in the
FINRA and that has agreed (i) not to sell Securities within the United States of America, its
territories or possessions or to persons who are citizens thereof or residents therein; (ii) that
any and all sales of Securities shall be in compliance with Rule 2110-01 of FINRA’s Conduct Rules;
(iii) to comply, as though it were a member of the FINRA, with Rules 2730, 2740 and 2750 of FINRA’s
Conduct Rules, and to comply with Rule 2420 thereof as that Rule applies to a non-member broker or
dealer in a foreign country.

     (c) There are no legal or governmental proceedings pending to which the Placement Agent is a
party or of which any of its properties is the subject or, to its Knowledge, threatened, which, if
determined adversely to the Placement Agent, would individually or in the aggregate materially and
adversely affect the Placement Agent’s ability to perform the Placement Agent’s obligations under
this Agreement.

     (d) No consent, approval, authorization or order of any court or governmental authority or
agency is required for the performance by the Placement Agent of its obligations under this
Agreement, except such as may be required by FINRA or state securities or “blue sky” laws.

     (e) This Agreement has been duly and validly executed and delivered by or on behalf of the
Placement Agent and constitutes a legal, valid, and binding obligation of the Placement Agent
enforceable in accordance with its terms, except to the extent that its enforceability is limited
by (a) applicable bankruptcy, insolvency, reorganization, moratorium, or other laws of general
application relating to or affecting the enforcement of creditors’ rights generally, and (b) laws
relating to the availability of specific performance, injunctive relief, or other equitable
remedies and except as enforceability of the indemnity and contribution provisions contained in
Section 7 hereof may be limited by applicable law or principles of public policy.

     (f) The Placement Agent shall not, without the prior written consent of the Company, which
consent shall not be unreasonably withheld, engage any Agent for the purpose of placing the
Securities.

     (g) The Placement Agent has not, during the Offering, (i) taken, directly or indirectly, any
action designed to cause or to result in the stabilization or manipulation of the price of any
security of the Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid
for, purchased, or, paid any

-9-

 

compensation for soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay to
any person any compensation for soliciting another to purchase any other securities of the Company.
The Placement Agent will not engage in over-allotment, stabilizing transactions or syndicate
covering transactions in connection with the Offering.

     5. Offering
and Sale of the Units. (a) Institutional Purchasers (as
described in Section 5(c) below) desiring to purchase Units will
be required to complete, execute, and deliver to the Placement Agents and the Company an executed
copy of the Subscription Agreement between such Purchaser and the Company.

     (b) Upon the Company’s acceptance of subscriptions (in its sole discretion), consummation of
the purchase and sale of the Units with respect to each Purchaser (a “Closing”), shall then
be made on the date or dates determined by the Company and the
Placement Agents (each “Closing Date”).

     (c) The Company agrees: (i) to pay the Placement Agents on the initial Closing Date and on any
subsequent Closing Date a cash placement fee (“Placement Agent Cash Fee”) of Seven (7%)
percent of the gross proceeds of the sale of the Units subscribed for by Purchasers in the Offering
on such Closing Date, and (ii) to issue to the Placement Agents (or their designees) warrants (the
“Placement Agent Warrants”) to purchase a number of shares of Common Stock of the Company
equal to 5% of the aggregate number of Units sold in the Offering on such Closing Date. The
Placement Agents agree to allocate the Placement Agent Cash Fee and Placement Agent Warrants among
themselves based upon the respective subscription amounts of Purchasers introduced by each of them,
and to any other Agents, on terms negotiated and reflected in the applicable selected dealer
agreements. Notwithstanding anything to the contrary, in the event
that any institutional Purchasers (all Purchasers except individuals,
retirement plans for an individual beneficiary or estate planning
entities established by one individual or a married couple) are
introduced by the Company, the Placement Agent Cash Fee and the Placement Agent Warrants payable
with respect to such Purchasers shall be paid 50% to each Placement Agent. The Placement Agent
Warrants shall (A) have a term of five (5) years from the
effective date of the Registration Statement of the Offering, (B) become
transferable and exercisable six months from the closing of the Offering, (C) have an exercise
price equal to 125% of the price of the Units purchased by Purchasers in the Offering and (D)
include a cashless exercise right available in the event the Common Stock underlying such Placement
Agent Warrants are not covered by an effective registration statement filed with the Commission at
the time of such exercise, and shall otherwise comply with FINRA Conduct Rule 2710. The Company
will also reimburse the Placement Agents, upon request, for (1) reasonable and documented expenses
(with supporting invoices/receipts) including, without limitation, the costs of delivering the
preliminary and final prospectuses to customers directly incurred in performing the services of
Placement Agent for the Offering (“Out-of-Pocket Expenses”), up to a maximum of $20,000 per
Agent and (2) legal fees and disbursements of the Placement Agents’ respective counsel, not to
exceed $60,000 ($30,000 for each Placement Agent’s counsel). Carter Securities LLC acknowledges
the prior receipt of $5,000 for its Out-of-Pocket Expenses and the receipt of $10,000 by its
counsel, Feldman Weinstein & Smith LLP, in respect of its legal fees and disbursements. The
Company shall be responsible for any costs and expenses associated with filings, applications or
registrations with any governmental or regulatory body, including, without limitation, those
associated with FINRA, any sales under “blue sky” laws, and the laws of the foreign countries in
which the securities will be offered or sold that are required to be made by the Company. Fordham
Financial Management, Inc.’s legal counsel, Morse & Morse, PLLC, shall act as “blue sky” counsel
for a fixed fee of $20,000 (based on approximately 15 states to be qualified) plus disbursements
approved by the Company. Morse & Morse shall provide the Company a list of checks to be produced
in payment of such filing fees, which shall be provided by the Company promptly after request
therefore and Morse & Morse has received prior to the making of such filings, a $10,000
advance towards its fees. No prior Company approval shall be required
for routine disbursements such as overnight delivery services,
postage, copying of Blue Sky filings and the like. The respective balances of legal fees and disbursements due to Feldman
Weinstein & Smith LLP and Morse & Morse, PLLC shall be paid immediately upon (but only in the event
of) the Closing.

-10-

 

     (d) Neither the Placement Agents nor the Company shall, directly or indirectly, pay or award
any finder’s fees, commissions or other compensation to any person engaged by a potential investor
for investment advice as an inducement to such advisor to advise the purchase of the Units;
provided, however, that the Agent’s fees and other normal sales commissions payable to a registered
broker-dealer or other properly licensed person for selling the Units shall not be prohibited
hereby.

     (e) Placement Agents shall be responsible for all filings under FINRA Conduct Rule 2710, and
the Company shall pay the filing fee in connection therewith.

     6. Covenants and Agreements of the Company. The Company covenants and agrees with
each Placement Agent that:

     (a) It will cooperate with the Agents to enable the Securities to be qualified for sale or
eligible for offer and sale pursuant to an exemption from registration under the securities laws of
such jurisdictions as the Placement Agent may designate, subject to approval by the Company, and at
the Placement Agent’s request will make such applications and furnish such information as may be
required of it for that purpose; provided, however, that the Company shall not be
required to qualify to do business or to file a general consent to service of process in any such
jurisdiction or to subject itself to taxation. It will, from time to time, prepare and file such
statements and reports as are or may be required to continue such qualifications in effect for so
long a period as the Placement Agents may reasonably request for the distribution of the Units.

     (b) It will make available to the Placement Agents and each prospective purchaser of Units at
a reasonable time prior to the closing the opportunity to ask questions and receive answers
concerning the terms and conditions of the Offering and to obtain any additional information that
the Company possesses or can acquire without unreasonable effort or expense that is necessary to
verify the accuracy of any information in the SEC Reports or otherwise furnished by the Company to
the Placement Agents or any prospective purchaser of Units; provided, however, that the Company
shall not be required to disclose any material nonpublic information to any prospective or actual
purchaser of Units.

     (c) The Company will file all reports required by applicable law or registration with regard
to sales of the Units and use of the proceeds therefrom.

     (d) The Company and the Placement Agents shall enter into an escrow agreement with American
Stock Transfer & Trust Company in customary form and substance, into which all Purchaser
subscriptions shall be deposited pending Closing.

     7. Indemnification and Contribution.

     (a) In connection with the Company’s engagement of the Placement Agents as placement agent,
the Company hereby agrees to indemnify and hold harmless the Placement Agents and their respective
Affiliates and each sub-placement agent and/or selected dealer, and their respective controlling
persons, directors, officers, shareholders, agents and employees of any of the foregoing
(collectively the “Indemnified Persons”), from and against any and all claims, actions,
suits, proceedings (including those of shareholders), damages, liabilities and expenses incurred by
any of them (including the reasonable fees and expenses of counsel), (collectively a
“Claim”), which are (A) related to or arise out of (i) any actions taken or omitted to be
taken (including any untrue statements made or any statements omitted to be made) by the Company,
or (ii) any actions taken or omitted to be taken by any Indemnified Person in connection with the
Company’s engagement (directly or indirectly) of any Agent, or (B) otherwise relate to or arise out
of any Agent’s activities on the Company’s behalf hereunder and the Company shall reimburse each

-11-

 

such Indemnified Person for all expenses (including the reasonable fees and expenses of not
more than one counsel per Agent) incurred by such Indemnified Person in connection with
investigating, preparing or defending any such claim, action, suit or proceeding, whether or not in
connection with pending or threatened litigation in which any Indemnified Person is a party. The
Company will not, however, be responsible for any Claim, which is finally judicially determined to
have resulted from the gross negligence or willful misconduct of any person seeking indemnification
for such Claim or the result of a violation of any applicable federal or state securities laws or
FINRA rules or regulations by the Agent or any Indemnified Person. The Company further agrees that
no Indemnified Person shall have any liability to the Company in connection with services provided
hereunder except for any Claim incurred by the Company as a result of such Indemnified Person’s
gross negligence or willful misconduct or the result of a violation by such Indemnified Person of
any applicable federal or state securities laws or FINRA rules or regulations.

     (b) The Company further agrees that it will not, without the prior written consent of the
Placement Agents, settle, compromise or consent to the entry of any judgment in any pending or
threatened Claim in respect of which indemnification may be sought hereunder (whether or not any
Indemnified Person is an actual or potential party to such Claim, provided that if an Agent (or any
controlling persons, directors, officers, shareholders, agents or employees of such Agent) other
than one of the Placement Agents is an actual party to such Claim, the consent of such Agent shall
also be required), unless such settlement, compromise or consent includes an unconditional,
irrevocable release of each Indemnified Person from any and all liability arising out of such
Claim.

     (c) Promptly upon receipt by an Indemnified Person of notice of any complaint or the assertion
or institution of any Claim with respect to which indemnification is being sought hereunder, such
Indemnified Person shall notify the Company in writing of such complaint or of such assertion or
institution but failure to so notify the Company shall not relieve the Company from any obligation
it may have hereunder, except and only to the extent such failure prejudices the Company’s rights
and defenses. If the Company so elects, the Company will assume the defense of such Claim,
including the employment of counsel reasonably satisfactory to such Indemnified Person and the
payment of the fees and expenses of such counsel. In the event, however, that legal counsel to such
Indemnified Person reasonably determines that having common counsel would present such counsel with
a conflict of interest or if the defendant in, or target of, any such Claim, includes an
Indemnified Person and the Company, and legal counsel to such Indemnified Person reasonably
concludes that there may be legal defenses available to it or other Indemnified Persons different
from or in addition to those available to the Company, then such Indemnified Person may employ its
own separate counsel to represent or defend him, her or it in any such Claim and the Company shall
pay the reasonable fees and expenses of such counsel. Notwithstanding anything herein to the
contrary, if the Company fails to timely or diligently defend, contest, or otherwise protect
against any Claim, the relevant Indemnified Person shall have the right, but not the obligation, to
defend, contest, compromise, settle, assert crossclaims, or counterclaims or otherwise protect
against the same, and shall be fully indemnified by the Company therefor, including without
limitation, for the reasonable fees and expenses of its counsel and all amounts paid as a result of
such Claim or the compromise or settlement thereof. In addition, with respect to any Claim in
which the Company assumes the defense, the Indemnified Person shall have the right to participate
in such Claim and to retain his, her or its own counsel therefor at his, her or its own expense.

     (d) The Company agrees that if any indemnity sought by an Indemnified Person hereunder is held
by a court to be unavailable for any reason then (whether or not an Agent is the Indemnified
Person), the Company and each Agent shall contribute to the Claim for which such indemnity is held
unavailable in such proportion as is appropriate to reflect the relative benefits to the Company,
on the one hand, and the Agents on the other, subject to the limitation that in no event shall the
amount of any Agent’s contribution to such Claim exceed the amount of fees actually received by
such Agent from the Company pursuant to

-12-

 

the Engagement Letter and this Agreement. The Company hereby agrees that the relative benefits to
the Company, on the one hand, and each Agent on the other, shall be deemed to be in the same
proportion as (i) the total value paid or proposed to be paid or received by the Company or its
stockholders as the case may be, pursuant to the Offering (whether or not consummated) bears to
(ii) the fee paid or proposed to be paid to each Agent in connection with such engagement.

     (e) The Company’s indemnity, reimbursement and contribution obligations under this Agreement
shall be in addition to, and shall in no way limit or otherwise adversely affect any rights that
any Indemnified Person may have at law or at equity.

     8. Survival of Indemnities, Representations, Warranties, etc. The respective
representations and warranties of the Placement Agents and the Company as set forth in this
Agreement or made by them respectively, pursuant to this Agreement, shall remain in full force and
effect, regardless of any investigation made by or on behalf of the Placement Agents, the Company,
or any of the officers or directors of the Company or any controlling person, and shall survive
delivery of and payment for the Units for a period ending on the date two years subsequent to the
final Closing Date.

     9. Conditions of Agents’ Obligations. The Placement Agents’ and each other Agent’s
obligations hereunder are subject to the accuracy in all material respects at and (except as
otherwise stated herein) as of the date hereof and at and as of each Closing Date, of the
representations and warranties made herein by the Company to the compliance in all material
respects at and as of each Closing Date by the Company with its covenants and agreements herein
contained and other provisions hereof to be satisfied at or prior to each Closing Date and to the
following additional conditions:

     (a) the Placement Agent shall not have stated in writing prior to each Closing Date to the
Company that the Base Prospectus, Prospectus Supplement or any Exchange Act Document, or any
amendment or supplement thereto contains an untrue statement of fact which, in the Placement
Agent’s reasonable opinion, is material, or omits to state a fact which, in the reasonable opinion
of the Placement Agent, is necessary to make the statements therein, in light of the circumstances
under which they were made, not misleading.

     (b) the Placement Agent shall have received a certificate, dated the Closing Date, on behalf
of the Company by the Chief Executive Officer or the President and the chief financial or
accounting officer of the Company to the effect that:

     (i) To the best of the knowledge of the signers, the representations and warranties of
the Company in this Agreement are true and correct in all material respects at and as of the
Closing Date, and the Company has complied in all material respects with all the agreements
and satisfied in all material respects all the conditions on its part to be performed or
satisfied at or prior to the Closing Date;

     (ii) Between the date of this Agreement and the Closing Date, no litigation has been
instituted or, to the Knowledge of the Company, threatened against the Company or the
Company of a character required to be disclosed in an Exchange Act Document, that has not
been so disclosed to the Agents; and

     (iii) Between the date of this Agreement and the Closing Date, there has not been any
material adverse change in the financial condition, business, or results of operations of
the Company or the Company.

-13-

 

     (c) The Company shall have furnished to the Placement Agents such additional certificates as
the Placement Agents may have reasonably requested as to the accuracy, at and as of the Closing
Date, of the representations and warranties made herein by it, as to compliance at and as of the
Closing Date by it with its covenants and agreements herein contained and other provisions hereof
to be satisfied at or prior to the Closing Date and as to other conditions to the Agents’
obligations hereunder.

     (d) The Placement Agents shall have received from outside counsel to the Company such
counsel’s written opinion, addressed to the Placement Agents, with reliance language for any
authorized co-placement agent or selected dealer, date as of the Closing Date, in form and
substance reasonably satisfactory to the Placement Agents.

     (e) The Placement Agents shall have received a “cold comfort” letter, in customary form and
substance, from the Company’s independent auditors.

     If any of the conditions provided for in this Section 9 shall not have been satisfied when and as
required by this Agreement, this Agreement may be terminated by the Placement Agents by notifying
the Company of such termination in writing at or prior to a Closing Date, but the Placement Agents
shall be entitled to waive any of such conditions.

     10. Effective Date. This Agreement shall become effective upon execution hereof.

     11. Termination. (a) This Agreement may be terminated at any time by the Placement
Agents by notice to the Company (i) if at or prior to the Closing Date trading in securities on the
Trading Market shall have been suspended for longer than four consecutive hours or minimum or
maximum prices shall have been established on the Trading Market, or a banking moratorium shall
have been declared by New York or United States authorities; (ii) if at or prior to the Closing
Date there shall have been a material escalation of hostilities between the United States and any
foreign country, or any other material insurrection or armed conflict involving the United States
which, in the Placement Agent’s reasonable judgment, after consultation with the Company, makes it
impracticable or inadvisable to offer or sell the Units; or (iii) if there shall be any material
litigation or regulatory action, pending or threatened against or involving the Company, which, in
the reasonable judgment of the Placement Agents, after consultation with the Company, makes it
impracticable or inadvisable to offer or deliver the Units on the terms contemplated by this
Agreement.

     (b) This Agreement may be terminated by either the Placement Agents or the Company upon 10
days’ written notice to the other party or parties.

     (c) In the event of any termination of this Agreement under this or any other provision of
this Agreement, there shall be no liability of any party to this Agreement to any other party,
other than as provided in Sections 7 and 11(d).

     (d) If the Company terminates this Agreement for any reason (other than the Placement Agents’
material failure to comply with their respective obligations under this Agreement or material
breach of the Placement Agents’ representations and warranties) or the Offering fails to close
because of the Company’s breach of any representations or warranties contained in this Agreement or
the Company’s failure to fulfill its covenants and agreements contained in this Agreement, the
Company shall pay the Placement Agents’ Out-Of-Pocket Expenses and legal fees and approved
disbursements.

     12. Notices. Any notice, consent or other communication given pursuant to this
Agreement shall be in writing and shall be effective when (i) delivered personally, (ii) sent by
email, telex or telecopier (with receipt confirmed), provided that a copy is mailed registered
mail, return receipt

-14-

 

requested, or (iii) when received by the addressee, if sent by Express Mail, Federal Express or
other express delivery service (receipt requested), in each case to the appropriate addressee set
forth below:

	 	 	 
	If to CARTER:

	 	Carter Securities LLC
	 

	 	725 Fifth Avenue, 24 flr
	 

	 	New York, NY 10022
	 

	 	Attention: John C. Lipman, Chairman
	 

	 	Phone: 212.989-6899
	 
	 	 
	If to Fordham:

	 	Fordham Financial Management, Inc.
	 

	 	14 Wall Street, 18th Floor
	 

	 	New York, NY 10005
	 

	 	Attention: William Baquet, Chief Executive Officer and President
	 

	 	Phone: 212.732-8500
	 
	 	 
	If to the Company:

	 	PolyMedix
	 

	 	170 N. Radnor-Chester Road, Suite 300
	 

	 	Radnor, PA 19087-5221
	 

	 	Attention: Nicholas Landekic, President and Chief Executive Officer

     13. Successors. This Agreement shall inure to the benefit of and be binding upon each
Placement Agent, the Company, and their respective successors and legal representatives, except
that neither the Company nor either Placement Agent may, except as otherwise provided herein,
assign or transfer any of its rights or obligations under this Agreement without the prior written
consent of the other parties hereto.

     14. Applicable Law. This Agreement shall be governed by and construed in accordance
with the laws of the State of New York. Any judicial proceeding brought against either of the
parties to this agreement or any dispute arising out of this Agreement or any matter related hereto
may be brought in the courts of the State New York or in the United States District Court for the
Southern District of New York and, by its execution and delivery of this agreement, each party to
this Agreement accepts the jurisdiction of such courts. The foregoing consent to jurisdiction shall
not be deemed to confer rights on any person other than the parties to this Agreement. The
prevailing party in any such litigation shall be entitled to receive from the losing party or
parties all costs and expenses, including reasonable attorney fees, incurred by the prevailing
party.

Signature Page Follows

-15-

 

PYMX Placement Agency Agreement

     If the foregoing correctly sets forth our understanding please indicate your acceptance
thereof in the space provided below for that purpose, whereupon this letter and your acceptance
shall constitute a binding agreement between us.

	 	 	 	 	 
	 	 	Very truly yours,
	 
	 	 	 	 
	 	 	POLYMEDIX, INC.
	 
	 	 	 	 
	 

	 	By	 	 
	 

	 	 	 	 
	 

	 	Name:	 	 
	 

	 	 	 	 
	 

	 	Title:	 	 
	 

	 	 	 	 

Accepted as of the date first above written

	 	 	 	 	 	 	 
	CARTER SECURITIES, LLC	 	FORDHAM FINANCIAL MANAGEMENT, INC.
	 
	 	 	 	 	 	 
	By:

	 	 	 	By:	 	 
	 

	 	 
	 	 	 	 
	Name:

	 	 	 	Name:	 	 
	 

	 	 
	 	 	 	 
	Title:

	 	 	 	Title:	 	 
	 

	 	 
	 	 	 	 

-16-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00144-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00144-of-00352.parquet"}]]